NEW YORK (GenomeWeb) – AstraZeneca today announced four collaborations to implement CRISPR/cas9 genome editing technology across its drug discovery platform.
The firm's collaborators are the Wellcome Trust Sanger Institute, The Innovative Genomics Initiative, Thermo Fisher Scientific, and the Broad and Whitehead Institutes.